ClinicalTrials.gg
RecruitingNCT07454733VITALSUpdated Oct 8, 2026

Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?

An interventional study of Video recording and Notes Instruction in Amyotrophic Lateral Sclerosis (ALS), sponsored by Trustees of Dartmouth College. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Trustees of Dartmouth College · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 8, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Planned enrollment
5th of 307
800 · median 33
Started
2026
with 32 others
No phase
82 of 440
32 open now
Primary completion
2029-09
later than 97 of 128 live
Registered
420th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 5th largest by planned enrollment of the 307 interventional ones that give a count, is one of 33 that started in 2026, is one of 82 with no phase, reaches primary completion later than 97 of the 128 other live ones, and was the 420th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

92 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

Amyotrophic lateral sclerosis (ALS) is a fatal, rare neurodegenerative disease affecting 30,000 people in the United States. The gold standard of care for people with ALS is multidisciplinary clinics (MDC). In these multidisciplinary clinics, which occur every 3 to 4 months, people with ALS see up to 12 different healthcare providers (e.g., speech therapy, physical therapy, the ALS doctor). These clinics can last from three to five hours, and across these three to five hours people with ALS and their caregivers receive a lot of information that is critical to the care and quality of life for people with ALS. However, this information can be difficult to remember given the large amount of information that is conveyed. The current standard for providing take-home information about the visit is to provide patients with a written after-visit summary and access to their doctor's notes about the visit, typically through the patient portal. This study tests whether providing participants with video recordings of their MDC visits improves their quality of life and the quality of life of their caregivers. The study will enroll 400 pairs of people with ALS and their caregivers from eight different sites in the United States. Half of the participants in the study will receive their after-visit summary notes (the NOTES condition) and the other half of the participants will receive both their summary notes, but will also receive video recordings of their MDC visits that they can watch on their own at home (the VIDEO condition). The study will last for 12 months, with participants receiving NOTES or VIDEO at each of their regularly-scheduled MDCs during the 12 months. The study will test whether caregiver and patient participants in the VIDEO condition experience better quality of life than those in the NOTES condition at 1 month, 6 months, and 12 months from study enrollment. The results of this study will help determine what is the most effective approach to communicating MDC information to people with ALS and their caregivers.

Read the detailed description

BACKGROUND AND SIGNIFICANCE

Amyotrophic lateral sclerosis (ALS) is a fatal, rare neurodegenerative disease affecting 30,000 people in the United States. People with ALS (pwALS) and their caregivers, attend 3 - 5 hour long multidisciplinary clinics (MDC) every 3 months where they meet with up to 12 specialists. The goal of treatment is to maintain pwALS quality of life (QOL). Optimal information from MDCs is necessary for the intensive at-home management which gets more complex as ALS progresses. Yet 40% of recommendations are forgotten by pwALS negatively impacting QOL, while caregivers report information deficits increasing caregiving burden. Patient portal access to MDC notes is standard, and can improve recall and health outcomes, yet concerns exist about their layout, comprehensiveness and challenges for people with low health literacy. An underutilized strategy to share MDC information is video recording. Systematic reviews find recordings improve health outcomes, and the use of video in an ALS context may be particularly helpful given complicated at-home management. The study will determine what is the most effective approach to communicating MDC information to facilitate optimal delivery of care for pwALS and their caregivers

STUDY AIMS

Aim 1. Assess the comparative effectiveness of written MDC visit information provided to pwALS and their caregivers via the patient portal (NOTES) versus NOTES plus visit video recording (VIDEO) on patient and caregiver quality of life.

Aim 2. Determine whether patient and caregiver health literacy and rapid ALS disease progression are modifying factors on the comparative effectiveness of NOTES versus VIDEO on primary outcomes.

Aim 3. Identify system and patient-level factors that impact the implementation and use of multimodal strategies of MDC information exchange by a diverse sample of pwALS, caregivers, clinicians and health system leaders.

Hypothesis (Main Effect): Compared to those receiving NOTES, pwALS randomized to also receive routine VIDEO recordings of their MDC visit will report better QOL via improved care-management (i.e., treatment adherence), self-management ability, satisfaction with communication and reduced healthcare utilization at 12 months; there will be larger relative benefits for pwALS, and caregivers, with low health literacy and rapid disease progression. The investigators also hypothesize that compared to NOTES alone, caregivers in the VIDEO arm will report better QOL, improved preparedness and less burden at 12 months.

STUDY DESCRIPTION

Overall study design

This study is a multisite, two-arm, parallel group, patient-randomized, controlled, comparative effectiveness trial with 12-month follow-up. Adopting a Hybrid Type 1 design, the investigators will also examine implementation barriers and facilitators using interviews guided by the Consolidated Framework for Implementation Research Framework 2.0.

Comparators

Comparator 1 (NOTES): After the initial MDC study staff will provide a 15-minute training to orient participants to the portal and how to access visit notes.

Comparator 2 (VIDEO): All MDC visits will be video-recorded over 12 months, using HealthPAL, an NIH-funded HIPAA-compliant personal health library developed by PI Barr. Participants in the VIDEO arm will receive orientation to the patient portal and HealthPAL.

Following each scheduled MDC, pwALS and caregivers in both groups will receive emails reminding them to watch the visit video recording and/or review their note: 1) within 48 hours of the visit to remind them of the visit discussion and self-management tasks they may have; and 2) 3 days before their next MDC visit to prepare for their next MDC visit.

Study Population

The study recruit 400 patient and caregiver pairs (400 pwALS and their 400 caregivers) from eight MDC sites (∼50 pairs per site): Dartmouth Health (Lebanon, NH), Massachusetts General Hospital (Boston, MA), Mayo Clinics (Scottsdale, AZ, and Jacksonville, FL), Penn State Health (Hershey, PA), University of Pittsburgh Medical Center (Pittsburgh, PA), University of Wisconsin (Madison, WI) and Virginia Commonwealth University (Richmond, VA). The study will include pwALS, age ≥18 years, who plan to attend MDC visits for 12-months, speak English or Spanish, have ≥12 months projected survival, and internet access and their primary caregivers (family member or friend), ≥18 years who attends MDC visits or assist with their care.

Outcomes

Primary outcomes: For people with ALS, the total score on the ALSAQ-40 (a self report survey measure of quality of life for people with ALS) is the primary outcome. For caregivers, the total score on the PROMIS-10 (a self report survey measure of quality of life); Secondary outcomes include exercise adherence, medication adherence, adherence to MDC recommendations, self-management ability, patient satisfaction with communication, caregiver visit engagement, preparedness for caregiving, and caregiver burden. Exploratory outcomes include healthcare utilization.

Timeframe

Twelve-month follow-up for all outcomes.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)

Keywords

  • amyotrophic lateral sclerosis (ALS)
  • Open Notes
  • Open Recordings
  • video recording
  • after-visit summaries
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for People with ALS:

  • Diagnosis of ALS by either El- Escorial or Gold Coast Criteria
  • ≥18 years of age
  • Plan to attend MDC visits for 12 months
  • Speak English or Spanish
  • Presence of a caregiver (defined as someone who assists with care) who is also participating in the VITALS trial
  • Projected of at least 12 months as determined by the site investigator.

Exclusion Criteria for People with ALS:

  • Unable or unwilling to provide or follow study procedures
  • Significant cognitive impairment, clinical dementia, or unstable psychiatric illness (including, but not limited to, psychosis, active suicidal ideation, suicide attempt, or untreated major depression) as determined by the site investigator
  • Current pregnancy based on participant self-report;
  • Unable to access the internet;
  • Do not have access to a personal or shared email and are not interested in creating a personal or shared email;
  • Do not wish to create a patient portal account, if they do not already have one;
  • Uncorrected hearing or visual impairment that would impair the ability to view video recordings;
  • Incarcerated.

Inclusion Criteria for Caregivers:

  • Agree to their identified role as a caregiver of a patient with ALS participating in the VITALS trial;
  • Speak English or Spanish;
  • ≥18 years of age.

Exclusion Criteria for Caregivers:

  • Unable or unwilling to provide consent or follow study procedures;
  • Unable to access the internet;
  • Do not have access to a personal or shared email and are not interested in creating a personal or shared email;
  • Uncorrected hearing or visual impairment;
  • Professional caregiver for the patient;
  • Incarcerated.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    VIDEO

    Participants in this arm of the study will have their multidisciplinary clinic visits video recorded and they will be able to access those video recordings on their own at home. They will also be able to access their doctor's notes and after visit summaries through their patient portal.

    Behavioral: Video recording · Behavioral: Notes Instruction

  • Active comparator
    NOTES

    Participants in this arm of the study will have their standard access to their doctor's notes and after visit summaries through their patient portal. They will also be provided with training on how to access and share access to their patient portal notes.

    Behavioral: Notes Instruction

Interventions

  • BehavioralVideo recording

    We will video record participants' multidisciplinary clinic (MDC) visits for 12 months. Participants will access the videos in HealthPAL, an NIH-funded, HIPAA-compliant personal health library developed with older adults and caregivers, available in Spanish and English. Each specialist visited with during the MDC will have a 'chapter' in HealthPAL that can be reviewed online at home by participants. Participants will receive orientation and training on both their patient portal and HealthPAL, including how to review and share their recordings using a take-home manual (an instructions video is also available in HealthPAL).

  • BehavioralNotes Instruction

    Participants will be given instruction on how to view their after-visit summaries and doctors' notes in their patient portal, as well as how to give other trusted family members or friends access to their visit notes.

06

What researchers measure

Primary outcomes

  1. For Caregiver Participants: the total score on the PROMIS-10 self report survey

    The Patient-Reported Outcomes Measurement Information System-10 (PROMIS-10) is a self-report measure of quality of life. The PROMIS-10 will be administered to caregivers via a secure online survey. We will analyze the total score on the PROMIS-10 as the primary outcome for caregiver participants.

    Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.

  2. For Patient Participants: The total score on the ALSAQ-40 self report survey.

    The Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) is a self-report measure of quality of life for people with ALS. The ALSAQ-40 will be administered via a secure online survey.

    Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.

Secondary outcomes

  1. Total Score on the Patient Activation Measure Short Form (PAM-SF)

    The PAM-SF is a self-reported measure of self-management ability. It will be administered to participants with ALS via a secure online survey.

    Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.

  2. Total Score on the Exercise Adherence Rating Scale (EARS)

    The EARS is a self-report measure of exercise adherence. It will be administered to participants with ALS via a secure online survey.

    Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.

  3. Total Score on the Adherence to Refills and Medications Scale (ARMS)

    The ARMS is a self-report measure of medication adherence. It will be administered to participants with ALS via a secure online survey.

    Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.

  4. Total Score on the Adherence to Multidisciplinary Clinic Recommendations

    Using a secure online survey, participants with ALS will indicate which of a list of possible clinic recommendations they received and the extent to which they adhered to those recommendations.

    Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.

  5. Total Score on the Interpersonal Processes of Care (IPC) Survey

    The IPC is a self-report measure of satisfaction with the communication during a doctor visit. It will be administered via a secure online survey to participants with ALS.

    Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.

  6. Total Score on the Caregiver Perceptions About Communication with Clinical Team (CAPACITY) Survey

    CAPACITY is a self-report measure of satisfaction with the communication during a doctor visit. It will be administered via a secure online survey to caregivers attending multidisciplinary clinic visits with the patient participants.

    Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.

  7. Total Score on the Preparedness for Caregiving Scale

    The Preparedness for Caregiving Scale is a self-report measure, completed by the caregiver, of the caregiver's self-perceived readiness to provide care across different domains (e.g., physical, emotional). It will be administered to caregivers via a secure online survey.

    Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.

  8. Total Score on the Burden Scale for Family Caregivers - Short Form (BSFC)

    The BSFC is a self-report measure of caregiver burden. It will be administered via a secure online survey to participant caregivers.

    Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.

Other outcomes

  1. Total number of patient phone calls and patient portal messages to the clinical care team.

    Collected using the participant with ALS's electronic medical record.

    Time frame: From enrollment to 12 months after enrollment.

  2. Total number of emergency room visits and hospitalizations.

    Collected from the participant with ALS's electronic medical record.

    Time frame: From enrollment to 12 months after enrollment.

07

Study locations

1 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified non-video data that will be shared include demographic data (e.g., age, gender, language, race, ethnicity, income); information on use of the patient portal and video recordings; researcher field notes (e.g., if a caregiver is present at a visit, whether the visit was telehealth or in-person); participant-reported survey responses (e.g., assessments measuring cognitive function, health literacy, quality of life, adherence, self-management ability, caregiver burden, caregiver preparedness). We will also share raw video recordings of the participants' multidisciplinary clinic visits. Raw video recordings will not be accompanied by personal identifying information, but they will not be stripped of any visual or auditory features that could potentially identify an individual.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: We anticipate IPD data being available for sharing within 1 year of the study close (September 2031) in perpetuity.

Access criteria: Data will be stored in a secured data archive. Access to the data will be restricted and available only upon request from researchers with a clear research plan for the data, whom have IRB approval, and the training and resources to carry out the research plan.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Sep 2029, 36 months after the start.

Of 134 non-industry interventional studies with no phase under Amyotrophic Lateral Sclerosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 36 months is close to that.

Counting every sponsor, half of 154 studies reached it within 35 months; a quarter within 23 and three quarters within 60.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 6, 2026
StartActual
Aug 12, 2026was Jun 2026
Primary completionEst.
Sep 1, 2029
CompletionEst.
Oct 1, 2029
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
7 sites changed recruiting status (6 now not yet recruiting, 1 now recruiting)
Show 7 sites
  • Mayo Clinic Scottsdale · Scottsdale, United Statesno status→Not yet recruiting
  • Mayo Clinic Jacksonville · Jacksonville, United Statesno status→Not yet recruiting
  • Massachusetts General Hospital · Boston, United Statesno status→Not yet recruiting
  • Dartmouth-Hitchcock Health · Lebanon, United Statesno status→Recruiting
  • Penn State Health Milton S. Hersey Medical Center · Hershey, United Statesno status→Not yet recruiting
  • University of Pittsburgh Medical Center · Pittsburgh, United Statesno status→Not yet recruiting
  • University of Wisconsin Health · Madison, United Statesno status→Not yet recruiting
Oct 8, 2026
Start date
Jun 1, 2026→Aug 12, 2026 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Recruiting
    7 sites changed recruiting status (6 now not yet recruiting, 1 now recruiting)
    Show 7 sites
    • Mayo Clinic Scottsdale · Scottsdale, United Statesno status→Not yet recruiting
    • Mayo Clinic Jacksonville · Jacksonville, United Statesno status→Not yet recruiting
    • Massachusetts General Hospital · Boston, United Statesno status→Not yet recruiting
    • Dartmouth-Hitchcock Health · Lebanon, United Statesno status→Recruiting
    • Penn State Health Milton S. Hersey Medical Center · Hershey, United Statesno status→Not yet recruiting
    • University of Pittsburgh Medical Center · Pittsburgh, United Statesno status→Not yet recruiting
    • University of Wisconsin Health · Madison, United Statesno status→Not yet recruiting
    Start date Jun 1, 2026→Aug 12, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07454733
Lead sponsor
Trustees of Dartmouth College
Collaborators
Patient-Centered Outcomes Research Institute, Massachusetts General Hospital, Dartmouth-Hitchcock Medical Center, University of Pittsburgh Medical Center, Penn State Health Milton S Hershey Medical Center, University of Wisconsin, Madison, Mayo Clinic
Responsible party
Paul J. Barr (Professor, Trustees of Dartmouth College) — Principal investigator
First posted
Mar 6, 2026
Start date
Aug 12, 2026
Primary completion
Sep 1, 2029 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Oct 8, 2026

Study contacts

Paul J Barr, PhD
Contact
paul.j.barr@dartmouth.edu
603-646-7016
Kelly M Goedert, PhD
Contact
kelly.m.goedert@dartmouth.edu
603-646-6976
Paul J Barr, PhD
principal investigator · Dartmouth College
Suma Babu, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion